- Conditions
- Malignant Glioma
- Interventions
- Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 7,250
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- riliprubart, Placebo, IVIg
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 32
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
- Conditions
- Head and Neck Cancer
- Interventions
- filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Assessment of Therapy Complications, Carboplatin, Filgrastim, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 75 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 357
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more
- Conditions
- Medication Adherence
- Interventions
- MESA
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 16 Years to 24 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Kidney Cancer
- Interventions
- becatecarin
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pulmonary Embolism
- Interventions
- Indigo Aspiration System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 58
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 48 more
- Conditions
- Acute Anemia
- Interventions
- SANGUINATE™
- Drug
- Lead sponsor
- Prolong Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Prescott, Arizona • Baldwin Park, California + 26 more
- Conditions
- HIV Infections, Meningitis
- Interventions
- Quadrivalent meningococcal conjugate vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 35
- States / cities
- Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
- Conditions
- Obesity
- Interventions
- pramlintide acetate, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 21
- States / cities
- Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
- Conditions
- Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- therapeutic melatonin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- vorinostat, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 8 more
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
- Interventions
- 131-I-TM-601, 131I-TM601
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Anemia
- Interventions
- INTERCEPT, Control
- Device
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction
- Interventions
- TNX-1300 (Injection), Placebo (Injection)
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Detroit, Michigan + 2 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Rovalpituzumab Tesirine
- Drug
- Lead sponsor
- Stemcentrx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, tirapazamine, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 87
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 397
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 1,613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 522
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 5 more